{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T18:31:16Z","timestamp":1790188276203,"version":"4.1.0"},"reference-count":124,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,3,13]],"date-time":"2023-03-13T00:00:00Z","timestamp":1678665600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>Patients with cancer represent a particularly vulnerable population at risk of adverse outcomes related to COVID-19. Collectively, the initial studies, including patients with and without cancer, confirmed that patients with cancer had a higher risk of complications and death related to COVID-19. Subsequent studies on patients with COVID-19 and cancer investigated patient and disease-related factors associated with COVID-19 severity and morality. Multiple interconnected factors include demographics, comorbidities, cancer-associated variables, treatment side effects, and other parameters. However, there is a lack of clarity on the contributions of any one factor. In this commentary, we deconvolute the data of specific risk factors associated with worse outcomes due to COVID-19 in cancer patients and focus on understanding the recommended guidelines to mitigate COVID-19 risk in this vulnerable population. In the first section, we highlight the key parameters, including age and race, cancer status, type of malignancy, cancer therapy, smoking status and comorbidities that impact outcomes for cancer patients with COVID-19. Next, we discuss efforts made at the patient, health system, and population levels to mitigate the effects of the ongoing outbreak for patients with cancer, including (1) screening, barrier and isolation strategies (2), Masking\/PPE (3), vaccination, and (4) systemic therapies (e.g., evusheld) to prevent disease onset in patients. In the last section, we discuss optimal treatment strategies for COVID-19, including additional therapies for patients with COVID-19 and cancer. Overall, this commentary focuses on articles with high yield and impact on understanding the evolving evidence of risk factors and management guidelines in detail. We also emphasize the ongoing collaboration between clinicians, researchers, health system administrators and policymakers and how its role will be important in optimizing care delivery strategies for patients with cancer. Creative patient-centered solutions will be critical in the coming years, post the pandemic.<\/jats:p>","DOI":"10.3389\/fonc.2023.1107384","type":"journal-article","created":{"date-parts":[[2023,3,13]],"date-time":"2023-03-13T05:26:36Z","timestamp":1678685196000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":8,"title":["Cancer, more than a \u201cCOVID-19 co-morbidity\u201d"],"prefix":"10.3389","volume":"13","author":[{"given":"Chinmay T.","family":"Jani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert T.","family":"Schooley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rana R.","family":"Mckay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott M.","family":"Lippman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,3,13]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-21-1368","article-title":"Learning through a pandemic: The current state of knowledge on COVID-19 and cancer","volume":"12","author":"Elkrief","year":"2022","journal-title":"Cancer Discovery"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djab097","article-title":"Impact of the COVID-19 pandemic on breast cancer mortality in the US: Estimates from collaborative simulation modeling","volume":"113","author":"Alagoz","year":"2021","journal-title":"J Natl Cancer Inst"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-021-01324-x","article-title":"COVID-19 and cancer registries: Learning from the first peak of the SARS-CoV-2 pandemic","volume":"124","author":"Lee","year":"2021","journal-title":"Br J Cancer"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.01074","article-title":"Outcomes of COVID-19 in patients with cancer: Report from the national COVID cohort collaborative (N3C)","volume":"39","author":"Sharafeldin","year":"2021","journal-title":"J Clin Oncol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2020.0980","article-title":"SARS-CoV-2 transmission in patients with cancer at a tertiary care hospital in Wuhan, China","volume":"6","author":"Yu","year":"2020","journal-title":"JAMA Oncol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2002032","article-title":"Clinical characteristics of coronavirus disease 2019 in China","volume":"382","author":"Guan","year":"2020","journal-title":"N Engl J Med"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(20)30096-6","article-title":"Cancer patients in SARS-CoV-2 infection: A nationwide analysis in China","volume":"21","author":"Liang","year":"2020","journal-title":"Lancet Oncol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2020.2648","article-title":"Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: Summary of a report of 72314 cases from the Chinese center for disease control and prevention","volume":"323","author":"Wu","year":"2020","journal-title":"JAMA"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2020.6775","article-title":"Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the new York city area","volume":"323","author":"Richardson","year":"2020","journal-title":"JAMA"},{"key":"B10","doi-asserted-by":"publisher","first-page":"m1966","DOI":"10.1136\/bmj.m1966","article-title":"Factors associated with hospital admission and critical illness among 5279 people with coronavirus disease 2019 in new York city: Prospective cohort study","volume":"369","author":"Petrilli","year":"2020","journal-title":"BMJ"},{"key":"B11","doi-asserted-by":"publisher","first-page":"S992","DOI":"10.1016\/j.annonc.2020.08.1735","article-title":"1670O prospective data of first 1,797 hospitalised patients with cancer and COVID-19 derived from the COVID-19 clinical information network and international severe acute respiratory and emerging infections consortium, WHO coronavirus clinical characterisation consortium","volume":"31","author":"Palmieri","year":"2020","journal-title":"Ann Oncol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"m1985","DOI":"10.1136\/bmj.m1985","article-title":"Features of 20 133 UK patients in hospital with covid-19 using the ISARIC WHO clinical characterisation protocol: Prospective observational cohort study","volume":"369","author":"Docherty","year":"2020","journal-title":"BMJ"},{"key":"B13","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1016\/j.annonc.2021.02.024","article-title":"Association of clinical factors and recent anticancer therapy with COVID-19 severity among patients with cancer: A report from the COVID-19 and cancer consortium","volume":"32","author":"Grivas","year":"2021","journal-title":"Ann Oncol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2021.6199","article-title":"Time-dependent COVID-19 mortality in patients with cancer: An updated analysis of the OnCovid registry","volume":"8","author":"OnCovid Study","year":"2022","journal-title":"JAMA Oncol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020008824","article-title":"Outcomes of patients with hematologic malignancies and COVID-19: A systematic review and meta-analysis of 3377 patients","volume":"136","author":"Vijenthira","year":"2020","journal-title":"Blood"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2020.6178","article-title":"Analyses of risk, racial disparity, and outcomes among US patients with cancer and COVID-19 infection","volume":"7","author":"Wang","year":"2021","journal-title":"JAMA Oncol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2020.09.027","article-title":"Dutch Oncology COVID-19 consortium: Outcome of COVID-19 in patients with cancer in a nationwide cohort study","volume":"141","author":"de Joode","year":"2020","journal-title":"Eur J Cancer"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1097\/HS9.0000000000000538","article-title":"Risk factors and mortality of COVID-19 in patients with lymphoma: A multicenter study","volume":"5","author":"Regalado-Artamendi","year":"2021","journal-title":"Hemasphere"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2022.0130","article-title":"Mortality among adults with cancer undergoing chemotherapy or immunotherapy and infected with COVID-19","volume":"5","author":"Varnai","year":"2022","journal-title":"JAMA Netw Open"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.592891","article-title":"COVID-19-Induced modifications in the tumor microenvironment: Do they affect cancer reawakening and metastatic relapse","volume":"10","author":"Francescangeli","year":"2020","journal-title":"Front Oncol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.01307","article-title":"Chemotherapy and COVID-19 outcomes in patients with cancer","volume":"38","author":"Jee","year":"2020","journal-title":"J Clin Oncol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-020-0979-0","article-title":"Determinants of COVID-19 disease severity in patients with cancer","volume":"26","author":"Robilotti","year":"2020","journal-title":"Nat Med"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-020-2521-4","article-title":"Factors associated with COVID-19-related death using OpenSAFELY","volume":"584","author":"Williamson","year":"2020","journal-title":"Nature"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(20)30442-3","article-title":"COVID-19 prevalence and mortality in patients with cancer and the effect of primary tumour subtype and patient demographics: A prospective cohort study","volume":"21","author":"Lee","year":"2020","journal-title":"Lancet Oncol"},{"key":"B25","doi-asserted-by":"publisher","first-page":"1366","DOI":"10.1016\/j.annonc.2020.10.312","article-title":"Clinical portrait of the SARS-CoV-2 epidemic in European cancer patients","volume":"31","author":"Pinato","year":"2020","journal-title":"Cancer Discov"},{"key":"B26","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1186\/s13045-020-00970-7","article-title":"Impact of hematologic malignancy and type of cancer therapy on COVID-19 severity and mortality: Lessons from a large population-based registry study","volume":"13","author":"Garcia-Suarez","year":"2020","journal-title":"J Hematol Oncol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(20)30251-9","article-title":"Clinical characteristics and risk factors associated with COVID-19 severity in patients with haematological malignancies in Italy: A retrospective, multicentre, cohort study","volume":"7","author":"Passamonti","year":"2020","journal-title":"Lancet Haematol"},{"key":"B28","doi-asserted-by":"publisher","first-page":"892","DOI":"10.1111\/bjh.17937","article-title":"Key findings from the UKCCMP cohort of 877 patients with haematological malignancy and COVID-19: Disease control as an important factor relative to recent chemotherapy or anti-CD20 therapy","volume":"196","author":"Booth","year":"2022","journal-title":"Br J Haematol"},{"key":"B29","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1182\/blood-2020-141937","article-title":"Severity of sars-Cov-2 infection in patients with hematologic malignancies: A COVID-19 and cancer consortium (CCC19) registry analysis","volume":"136","author":"Rubinstein","year":"2020","journal-title":"Blood"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2021005691","article-title":"A prognostic model for patients with lymphoma and COVID-19: A multicentre cohort study","volume":"6","author":"Visco","year":"2022","journal-title":"Blood Adv"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020006965","article-title":"Outcomes of COVID-19 in patients with CLL: A multicenter international experience","volume":"136","author":"Mato","year":"2020","journal-title":"Blood"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2020.269878","article-title":"Immunologic characterization of COVID-19 patients with hematological cancer","volume":"106","author":"Maia","year":"2020","journal-title":"Haematologica"},{"key":"B33","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1016\/j.ccell.2020.09.007","article-title":"SARS-CoV-2 viral load predicts mortality in patients with and without cancer who are hospitalized with COVID-19","volume":"38","author":"Westblade","year":"2020","journal-title":"Cancer Cell"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1200\/OP.21.00394","article-title":"Changes over time in COVID-19 severity and mortality in patients undergoing cancer treatment in the united states: Initial report from the ASCO registry","volume":"18","author":"Mileham","year":"2022","journal-title":"JCO Oncol Pract"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.16852","article-title":"Clinical outcome of coronavirus disease 2019 in haemato-oncology patients","volume":"190","author":"Aries","year":"2020","journal-title":"Br J Haematol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.16801","article-title":"Survival study of hospitalised patients with concurrent COVID-19 and haematological malignancies","volume":"190","author":"Martin-Moro","year":"2020","journal-title":"Br J Haematol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1097\/HS9.0000000000000547","article-title":"SARS-CoV-2 vaccines in patients with multiple myeloma","volume":"5","author":"Gavriatopoulou","year":"2021","journal-title":"Hemasphere"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-020-0870-5","article-title":"CLL and COVID-19 at the hospital clinic of Barcelona: An interim report","volume":"34","author":"Baumann","year":"2020","journal-title":"Leukemia"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-020-0959-x","article-title":"COVID-19 severity and mortality in patients with chronic lymphocytic leukemia: a joint study by ERIC, the European research initiative on CLL, and CLL campus","volume":"34","author":"Scarfo","year":"2020","journal-title":"Leukemia"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2021011568","article-title":"Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with chronic lymphocytic leukemia","volume":"137","author":"Herishanu","year":"2021","journal-title":"Blood"},{"key":"B41","article-title":"On behalf of the CCC-19 consortium. understanding the impact of COVID in cancer patients through the COVID-19 and cancer (CCC-19) and other COVID consortiums. In: Proceedings of the AACR virtual meeting: COVID-19 and cancer","volume-title":"Clin Cancer Res","author":"Rini","year":"2020"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2021.10.009","article-title":"Life-prolonging treatment restrictions and outcomes in patients with cancer and COVID-19: an update from the Dutch oncology COVID-19 consortium","volume":"160","author":"de Joode","year":"2022","journal-title":"Eur J Cancer"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(20)30314-4","article-title":"COVID-19 in patients with thoracic malignancies (TERAVOLT): First results of an international, registry-based, cohort study","volume":"21","author":"Garassino","year":"2020","journal-title":"Lancet Oncol"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.3201\/eid2610.202792","article-title":"Coronavirus disease among persons with sickle cell disease, united states, march 20-may 21, 2020","volume":"26","author":"Panepinto","year":"2020","journal-title":"Emerg Infect Dis"},{"key":"B45","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1182\/blood-2020-137676","article-title":"Hospitalization and case fatality in individuals with sickle cell disease and COVID-19 infection","volume":"136","author":"Mucalo","year":"2020","journal-title":"Blood"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)31187-9","article-title":"Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study","volume":"395","author":"Kuderer","year":"2020","journal-title":"Lancet"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)31173-9","article-title":"COVID-19 mortality in patients with cancer on chemotherapy or other anticancer treatments: A prospective cohort study","volume":"395","author":"Lee","year":"2020","journal-title":"Lancet"},{"key":"B48","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.ejca.2020.09.028","article-title":"A systematic review and meta-analysis: The effect of active cancer treatment on severity of COVID-19","volume":"141","author":"Yekeduz","year":"2020","journal-title":"Eur J Cancer"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-20-0596","article-title":"Impact of PD-1 blockade on severity of COVID-19 in patients with lung cancers","volume":"10","author":"Luo","year":"2020","journal-title":"Cancer Discovery"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.2217\/imt-2020-0067","article-title":"Controversies about COVID-19 and anticancer treatment with immune checkpoint inhibitors","volume":"12","author":"Bersanelli","year":"2020","journal-title":"Immunotherapy"},{"key":"B51","doi-asserted-by":"publisher","first-page":"1824646","DOI":"10.1080\/2162402X.2020.1824646","article-title":"Immunotherapy or other anti-cancer treatments and risk of exacerbation and mortality in cancer patients with COVID-19: A systematic review and meta-analysis","volume":"9","author":"Wang","year":"2020","journal-title":"Oncoimmunology"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1002\/cac2.12077","article-title":"Clinical outcomes of coronavirus disease 2019 (COVID-19) in cancer patients with prior exposure to immune checkpoint inhibitors","volume":"40","author":"Wu","year":"2020","journal-title":"Cancer Commun (Lond)"},{"key":"B53","doi-asserted-by":"publisher","first-page":"10250","DOI":"10.1038\/s41598-020-67105-3","article-title":"Metabolomic and lipidomic profiling of bone marrow plasma differentiates patients with monoclonal gammopathy of undetermined significance from multiple myeloma","volume":"10","author":"Gonsalves","year":"2020","journal-title":"Sci Rep"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1002\/onco.13768","article-title":"Risk of COVID-19 in patients with cancer receiving immune checkpoint inhibitors","volume":"26","author":"Klebanov","year":"2021","journal-title":"Oncologist"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-001931corr1","article-title":"Clinical impact of COVID-19 on patients with cancer treated with immune checkpoint inhibition","volume":"9","author":"Rogiers","year":"2021","journal-title":"J Immunother Cancer"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.18632\/aging.203945","article-title":"Association of active immunotherapy with outcomes in cancer patients with COVID-19: A systematic review and meta-analysis","volume":"14","author":"Cao","year":"2022","journal-title":"Aging (Albany NY)"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-021-01466-0","article-title":"Poor outcome of patients with COVID-19 after CAR T-cell therapy for b-cell malignancies: Results of a multicenter study on behalf of the European society for blood and marrow transplantation (EBMT) infectious diseases working party and the European hematology association (EHA) lymphoma group","volume":"35","author":"Spanjaart","year":"2021","journal-title":"Leukemia"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(20)30429-4","article-title":"Clinical characteristics and outcomes of COVID-19 in haematopoietic stem-cell transplantation recipients: An observational cohort study","volume":"8","author":"Sharma","year":"2021","journal-title":"Lancet Haematol"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2022.01.010","article-title":"Immune response to three doses of mRNA SARS-CoV-2 vaccines in CD19-targeted chimeric antigen receptor T cell immunotherapy recipients","volume":"40","author":"Sesques","year":"2022","journal-title":"Cancer Cell"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2021.34330","article-title":"Association between androgen deprivation therapy and mortality among patients with prostate cancer and COVID-19","volume":"4","author":"Schmidt","year":"2021","journal-title":"JAMA Netw Open"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1007\/s11606-020-05991-z","article-title":"Charlson comorbidity index score and risk of severe outcome and death in Danish COVID-19 patients","volume":"35","author":"Christensen","year":"2020","journal-title":"J Gen Intern Med"},{"key":"B62","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.ejca.2020.09.035","article-title":"Risk factors for coronavirus disease 2019 (COVID-19) severity and mortality among solid cancer patients and impact of the disease on anticancer treatment: A French nationwide cohort study (GCO-002 CACOVID-19)","volume":"141","author":"Lievre","year":"2020","journal-title":"Eur J Cancer"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1016\/0021-9681(87)90171-8","article-title":"A new method of classifying prognostic comorbidity in longitudinal studies: Development and validation","volume":"40","author":"Charlson","year":"1987","journal-title":"J Chronic Dis"},{"key":"B64","doi-asserted-by":"publisher","first-page":"100104","DOI":"10.1016\/j.lanepe.2021.100104","article-title":"Changes in COVID-19 in-hospital mortality in hospitalised adults in England over the first seven months of the pandemic: An observational study using administrative data","volume":"5","author":"Gray","year":"2021","journal-title":"Lancet Reg Health Eur"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00573-8","article-title":"Prevalence and impact of COVID-19 sequelae on treatment and survival of patients with cancer who recovered from SARS-CoV-2 infection: Evidence from the OnCovid retrospective, multicentre registry study","volume":"22","author":"Pinato","year":"2021","journal-title":"Lancet Oncol"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.2196\/29279","article-title":"SMART COVID navigator, a clinical decision support tool for COVID-19 treatment: Design and development study","volume":"24","author":"Suraj","year":"2022","journal-title":"J Med Internet Res"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1016\/S2666-7568(22)00009-5","article-title":"Geriatric risk factors for serious COVID-19 outcomes among older adults with cancer: A cohort study from the COVID-19 and cancer consortium","volume":"3","author":"Elkrief","year":"2022","journal-title":"Lancet Healthy Longev"},{"key":"B68","unstructured":"ASCO COVID-19 data presented at AACR virtual annual meeting"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.4373","article-title":"Asymptomatic detection of SARS-CoV-2 among cancer patients receiving infusional anti-cancer therapy","volume":"10","author":"Shaya","year":"2021","journal-title":"Cancer Med"},{"key":"B70","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1101\/2020.04.13.20063933","article-title":"Impact of lockdown on COVID-19 epidemic in ile-de-France and possible exit strategies","volume":"18","author":"Di Domenico","year":"2020","journal-title":"BMC Med"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1007\/s00148-021-00868-9","article-title":"The effect of non-pharmaceutical interventions on the demand for health care and on mortality: Evidence from COVID-19 in Scandinavia","volume":"34","author":"Juranek","year":"2021","journal-title":"J Popul Econ"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.21873\/invivo.11963","article-title":"Lockdown during COVID-19: The Greek success","volume":"34","author":"Moris","year":"2020","journal-title":"In Vivo."},{"key":"B73","unstructured":"CDCUse personal protective equipment (PPE) when caring for patients with confirmed or suspected COVID-19"},{"key":"B74","unstructured":"FDACOVID-19 vaccines"},{"key":"B75","unstructured":"CDCStay up to date with COVID-19 vaccines including boosters"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00213-8","article-title":"Safety and immunogenicity of one versus two doses of the COVID-19 vaccine BNT162b2 for patients with cancer: Interim analysis of a prospective observational study","volume":"22","author":"Monin","year":"2021","journal-title":"Lancet Oncol"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1016\/j.jinf.2021.12.044","article-title":"Pfizer-BioNTech and Oxford AstraZeneca COVID-19 vaccine effectiveness and immune response amongst individuals in clinical risk groups","volume":"84","author":"Whitaker","year":"2022","journal-title":"J Infect"},{"key":"B78","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.ccell.2021.11.006","article-title":"Efficacy of booster doses in augmenting waning immune responses to COVID-19 vaccine in patients with cancer","volume":"40","author":"Shapiro","year":"2022","journal-title":"Cancer Cell"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2021.12.006","article-title":"COVID-19 vaccination and breakthrough infections in patients with cancer","volume":"33","author":"Schmidt","year":"2022","journal-title":"Ann Oncol"},{"key":"B80","unstructured":"Coronavirus (COVID-19) update: FDA authorizes new long-acting monoclonal antibodies for pre-exposure prevention of COVID-19 in certain individuals"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2021.6199","article-title":"Tixagevimab and cilgavimab (Evusheld) for pre-exposure prophylaxis of COVID-19","volume":"327","year":"2022","journal-title":"JAMA"},{"key":"B82","unstructured":"FDA Releases important information about risk of COVID-19 due to certain variants not neutralized by evusheld"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2102685","article-title":"Bamlanivimab plus etesevimab in mild or moderate covid-19","volume":"385","author":"Dougan","year":"2021","journal-title":"N Engl J Med"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(22)00163-5","article-title":"Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): A randomised, controlled, open-label, platform trial","volume":"399","author":"Group","year":"2022","journal-title":"Lancet"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2107934","article-title":"Early treatment for covid-19 with SARS-CoV-2 neutralizing antibody sotrovimab","volume":"385","author":"Gupta","year":"2021","journal-title":"N Engl J Med"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc2119407","article-title":"Efficacy of antibodies and antiviral drugs against covid-19 omicron variant","volume":"386","author":"Takashita","year":"2022","journal-title":"N Engl J Med"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiab377","article-title":"Real-world clinical outcomes of bamlanivimab and casirivimab-imdevimab among high-risk patients with mild to moderate coronavirus disease 2019","volume":"224","author":"Ganesh","year":"2021","journal-title":"J Infect Dis"},{"key":"B88","unstructured":"Therapeutic management of nonhospitalized adults with COVID-19"},{"key":"B89","unstructured":"Covid-19 treatment guidelines. therapeutic management of nonhospitalized adults with COVID-19"},{"key":"B90","unstructured":"CDCUnderlying medical conditions associated with higher risk for severe COVID-19: Information for healthcare professionals"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.5b01461","article-title":"An overview of severe acute respiratory syndrome-coronavirus (SARS-CoV) 3CL protease inhibitors: Peptidomimetics and small molecule chemotherapy","volume":"59","author":"Pillaiyar","year":"2016","journal-title":"J Med Chem"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.1126\/science.abl4784","article-title":"An oral SARS-CoV-2 m(pro) inhibitor clinical candidate for the treatment of COVID-19","volume":"374","author":"Owen","year":"2021","journal-title":"Science"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiab247","article-title":"Beta-d-N4-hydroxycytidine inhibits SARS-CoV-2 through lethal mutagenesis but is also mutagenic to mammalian cells","volume":"224","author":"Zhou","year":"2021","journal-title":"J Infect Dis"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2116044","article-title":"Molnupiravir for oral treatment of covid-19 in nonhospitalized patients","volume":"386","author":"Jayk Bernal","year":"2022","journal-title":"N Engl J Med"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2118542","article-title":"Oral nirmatrelvir for high-risk, nonhospitalized adults with covid-19","volume":"386","author":"Hammond","year":"2022","journal-title":"N Engl J Med"},{"key":"B96","unstructured":"Drug-drug interactions between ritonavir-boosted nirmatrelvir (Paxlovid) and concomitant medications"},{"key":"B97","unstructured":"PAXLOVID patient eligibility screening checklist tool for prescribers"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2116846","article-title":"Early remdesivir to prevent progression to severe covid-19 in outpatients","volume":"386","author":"Gottlieb","year":"2022","journal-title":"N Engl J Med"},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2007764","article-title":"Remdesivir for the treatment of covid-19 - final report","volume":"383","author":"Beigel","year":"2020","journal-title":"N Engl J Med"},{"key":"B100","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1056\/NEJMoa2023184","article-title":"Repurposed antiviral drugs for covid-19 - interim WHO solidarity trial results","volume":"384","author":"Consortium","year":"2021","journal-title":"N Engl J Med"},{"key":"B101","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1056\/NEJMoa2021436","article-title":"Dexamethasone in hospitalized patients with covid-19","volume":"384","author":"Group","year":"2021","journal-title":"N Engl J Med"},{"key":"B102","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-20-0941","article-title":"Utilization of COVID-19 treatments and clinical outcomes among patients with cancer: A COVID-19 and cancer consortium (CCC19) cohort study","volume":"10","author":"Rivera","year":"2020","journal-title":"Cancer Discovery"},{"key":"B103","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2022.18590","article-title":"Effect of ivermectin vs placebo on time to sustained recovery in outpatients with mild to moderate COVID-19: A randomized clinical trial","volume":"328","author":"Naggie","year":"2022","journal-title":"JAMA"},{"key":"B104","doi-asserted-by":"publisher","DOI":"10.1080\/1744666X.2019.1629904","article-title":"Tocilizumab for the treatment of chimeric antigen receptor T cell-induced cytokine release syndrome","volume":"15","author":"Kotch","year":"2019","journal-title":"Expert Rev Clin Immunol"},{"key":"B105","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.blre.2018.11.002","article-title":"Recent advances in CAR T-cell toxicity: Mechanisms, manifestations and management","volume":"34","author":"Brudno","year":"2019","journal-title":"Blood Rev"},{"key":"B106","doi-asserted-by":"publisher","DOI":"10.1016\/j.cllc.2020.08.002","article-title":"Tocilizumab for COVID-19 pneumonia in a patient with non-small-cell lung cancer treated with chemoimmunotherapy","volume":"22","author":"Bonomi","year":"2021","journal-title":"Clin Lung Cancer"},{"key":"B107","doi-asserted-by":"publisher","DOI":"10.1093\/icvts\/ivw158","article-title":"Comparison between caprini and padua risk assessment models for hospitalized medical patients at risk for venous thromboembolism: A retrospective study","volume":"23","author":"Liu","year":"2016","journal-title":"Interact Cardiovasc Thorac Surg"},{"key":"B108","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.114.001152","article-title":"External validation of the risk assessment model of the international medical prevention registry on venous thromboembolism (IMPROVE) for medical patients in a tertiary health system","volume":"3","author":"Rosenberg","year":"2014","journal-title":"J Am Heart Assoc"},{"key":"B109","doi-asserted-by":"publisher","DOI":"10.1055\/s-0040-1714275","article-title":"Thrombosis and hemostasis issues in cancer patients with COVID-19","volume":"46","author":"Horowitz","year":"2020","journal-title":"Semin Thromb Hemost."},{"key":"B110","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(21)00105-8","article-title":"COVID-19-associated coagulopathy and antithrombotic agents\u2013lessons after 1 year","volume":"8","author":"Leentjens","year":"2021","journal-title":"Lancet Haematol"},{"key":"B111","unstructured":"NICECOVID-19 rapid guidlines"},{"key":"B112","unstructured":"Tracking coronavirus vaccinations around the world"},{"key":"B113","unstructured":"Asco special report: A guide to cancer care during the coviddelivery 19 pandemic"},{"key":"B114","unstructured":"ESMOCancer patient management during the covid-19 pandemic"},{"key":"B115","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2020.04.003","article-title":"Cancer research after COVID-19: Where do we go from here","volume":"37","author":"Colbert","year":"2020","journal-title":"Cancer Cell"},{"key":"B116","unstructured":"NCI COVID-19 in cancer patients, NCCAPS study"},{"key":"B117","doi-asserted-by":"publisher","first-page":"e2148581","DOI":"10.1001\/jamanetworkopen.2021.48581","article-title":"Comparison of early- and late-stage breast and colorectal cancer diagnoses during vs before the COVID-19 pandemic","volume":"5","author":"Zhou","year":"2022","journal-title":"JAMA Netw Open"},{"key":"B118","doi-asserted-by":"publisher","DOI":"10.1136\/bmjspcare-2021-003301","article-title":"Newly diagnosed cancer and the COVID-19 pandemic: Tumour stage migration and higher early mortality","author":"Guven","year":"2021","journal-title":"BMJ Support Palliat Care"},{"key":"B119","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2020.7600","article-title":"Cancer screening tests and cancer diagnoses during the COVID-19 pandemic","volume":"7","author":"Bakouny","year":"2021","journal-title":"JAMA Oncol"},{"key":"B120","doi-asserted-by":"publisher","first-page":"1290","DOI":"10.1126\/science.abd3377","article-title":"COVID-19 and cancer","volume":"368","author":"Sharpless","year":"2020","journal-title":"Science"},{"key":"B121","doi-asserted-by":"publisher","DOI":"10.1200\/CCI.20.00134","article-title":"Impact of COVID-19 on cancer care: How the pandemic is delaying cancer diagnosis and treatment for American seniors","volume":"4","author":"Patt","year":"2020","journal-title":"JCO Clin Cancer Inform"},{"key":"B122","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1002\/cncr.33274","article-title":"The future of cancer screening after COVID-19 may be at home","volume":"127","author":"Gorin","year":"2021","journal-title":"Cancer"},{"key":"B123","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofab466.502","article-title":"300. long COVID in cancer patients: Preponderance of symptoms in majority of patients over long time period","volume-title":"Open forum infectious diseases","author":"Dagher","year":"2021"},{"key":"B124","doi-asserted-by":"publisher","first-page":"100767","DOI":"10.1016\/j.eclinm.2021.100767","article-title":"Understanding the survivorship burden of long COVID","volume":"33","author":"Iqbal","year":"2021","journal-title":"EClinicalMedicine"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2023.1107384\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,13]],"date-time":"2023-03-13T05:26:50Z","timestamp":1678685210000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2023.1107384\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,13]]},"references-count":124,"alternative-id":["10.3389\/fonc.2023.1107384"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2023.1107384","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,13]]},"article-number":"1107384"}}